SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Dec. 19, 2017– Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for the expanded indication of patients with…Original Article
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
